The 12-month price targets, analyzed by analysts, offer insights with an average target of $352.0, a high estimate of $425.00 ...

Fintel reports that on April 25, 2025, Wells Fargo downgraded their outlook for United Therapeutics (NasdaqGS:UTHR) from ...

In a report released today, Tiago Fauth from Wells Fargo downgraded United Therapeutics (UTHR – Research Report) to a Hold, with a price target ...

Wells Fargo downgraded United Therapeutics (UTHR) to Equal Weight from Overweight with a price target of $314, down from $395.Stay Ahead of the ...

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...

Interim long-term data from the ongoing ralinepag phase 3 ADVANCE EXTENSION open-label study to be presented at a mini symposium An annual update of the preliminary baseline data from the TETON ...

Across the recent three months, 4 analysts have shared their insights on United Therapeutics (NASDAQ:UTHR), expressing a variety of opinions spanning from bullish to bearish. In the table below ...